USPTO serial 86745982
SENZER
Reviewed by CopyMark Law Group
Reg. 5348473Status 710
- Filing date
- Status date
- Registration date
- Dec 5, 2017
- Examiner
- BEN, LINDSEY HEATHER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SENZER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of pain, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and hepatic, renal, intestinal, and cardiovascular disorders; substances adapted for medical use, namely, cannabinoids for the treatment of pain, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea and vomiting, stroke, cancer, drug dependence, drug addiction, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and hepatic, renal, other intestinal, neurological and cardiovascular disorders; vaccines for the treatment of pain, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea and vomiting, stroke, cancer, drug dependence, drug addiction, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and intestinal and cardiovascular disorders; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for the treatment of pain, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders; drug delivery agents in the form of powders, capsules, inhalers, that facilitate the delivery of pharmaceutical preparations; none of the aforesaid being for or in relation to preparations for the treatment of liver diseases | SECTION 8 - CANCELLED | — |
| 010 | Inhalers for medical purposes; filters for inhalers for medical purposes; inhalers for medical use; inhalers for therapeutic use; drug delivery systems; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems; microneedle arrays for delivering medications; hypodermic syringes for injections for medical purposes; all of the aforesaid for use in delivering pharmaceutical preparations for the treatment of pain, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, epilepsy, anxiety, depression, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis, nausea and vomiting, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, bacterial and fungal infections, osteoporosis, sepsis, mental illness, and intestinal, neurological and cardiovascular disorders; none of the aforesaid being for or in relation to preparations for the treatment of liver diseases | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kinhold IP Limited
- Other trademarks owned by Kinhold IP Limited
- Other trademarks owned by Kinhold IP Limited
- Other trademarks owned by SENZER LIMITED
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named SENZER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 21, 2024 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 14, 2023 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Sep 14, 2023 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Dec 5, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 26, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 5, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 19, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 14, 2017 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Aug 11, 2017 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Aug 7, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 26, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 26, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 24, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Feb 1, 2017 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Feb 1, 2017 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Feb 1, 2017 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jan 30, 2017 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 21, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 21, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 21, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 21, 2016 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 21, 2016 | PBMR | WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST | — |
| Jul 18, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 13, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 23, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 23, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 22, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 22, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 17, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 15, 2015 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Dec 15, 2015 | ALIE | ASSIGNED TO LIE | — |
| Dec 15, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 10, 2015 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Sep 8, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 5, 2015 | NWAP | NEW APPLICATION ENTERED | — |